Is ARDX or IMRX more profitable?

Immuneering has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Immuneering's return on equity of -31.93% beat Ardelyx's return on equity. Company Net Margins Return on Equity Return on Assets Ardelyx -13.58% -38.11% -11.85% Immuneering N/A -31.93% -29.92%

Does the media prefer ARDX or IMRX?

In the previous week, Immuneering had 2 more articles in the media than Ardelyx. MarketBeat recorded 6 mentions for Immuneering and 4 mentions for Ardelyx. Ardelyx's average media sentiment score of 1.02 beat Immuneering's score of 0.93 indicating that Ardelyx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immuneering 0 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, CRVS or IMRX?

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corvus Pharmaceuticals N/A N/A -$15.28M -$0.52 N/A Immuneering N/A N/A -$56.03M -$1.17 N/A

Is CRVS or IMRX more profitable?

Immuneering's return on equity of -31.93% beat Corvus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Corvus Pharmaceuticals N/A -38.92% -35.75% Immuneering N/A -31.93% -29.92%

Is IMRX or CAPR more profitable?

Immuneering's return on equity of -31.93% beat Capricor Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -31.93% -29.92% Capricor Therapeutics N/A -59.27% -48.65%

Does the media prefer IMRX or CAPR?

In the previous week, Immuneering had 4 more articles in the media than Capricor Therapeutics. MarketBeat recorded 6 mentions for Immuneering and 2 mentions for Capricor Therapeutics. Immuneering's average media sentiment score of 0.93 beat Capricor Therapeutics' score of 0.63 indicating that Immuneering is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 0 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Capricor Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, SVRA or IMRX?

Savara is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.56 N/A Immuneering N/A N/A -$56.03M -$1.17 N/A

Is SVRA or IMRX more profitable?

Immuneering's return on equity of -31.93% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -87.19% -66.42% Immuneering N/A -31.93% -29.92%

Which has stronger earnings & valuation, IMRX or AVLN?

Immuneering is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuneering N/A N/A -$56.03M -$1.17 N/A Avalyn Pharma N/A N/A N/A -$21.83 N/A

Is IMRX or AVLN more profitable?

Avalyn Pharma's return on equity of 0.00% beat Immuneering's return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -31.93% -29.92% Avalyn Pharma N/A N/A N/A

Does the media prefer IMRX or AVLN?

In the previous week, Immuneering had 3 more articles in the media than Avalyn Pharma. MarketBeat recorded 6 mentions for Immuneering and 3 mentions for Avalyn Pharma. Immuneering's average media sentiment score of 0.93 beat Avalyn Pharma's score of 0.62 indicating that Immuneering is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 0 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalyn Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Immuneering (IMRX) Competitors

$5.16 +0.05 (+0.98%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$5.15 -0.01 (-0.19%)

As of 07/13/2026 07:59 PM Eastern

Compare

IMRX vs. ARDX, CRVS, CAPR, SVRA, and AVLN

Should you buy Immuneering stock or one of its competitors? MarketBeat compares Immuneering with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immuneering include Ardelyx (ARDX), Corvus Pharmaceuticals (CRVS), Capricor Therapeutics (CAPR), Savara (SVRA), and Avalyn Pharma (AVLN). These companies are all part of the "pharmaceutical products" industry.

How does Immuneering compare to Ardelyx?

Ardelyx (NASDAQ:ARDX) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Immuneering has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Immuneering's return on equity of -31.93% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-13.58%	-38.11%	-11.85%
Immuneering	N/A	-31.93%	-29.92%

Ardelyx currently has a consensus price target of $15.73, indicating a potential upside of 205.98%. Immuneering has a consensus price target of $16.57, indicating a potential upside of 221.15%. Given Immuneering's higher possible upside, analysts plainly believe Immuneering is more favorable than Ardelyx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Immuneering had 2 more articles in the media than Ardelyx. MarketBeat recorded 6 mentions for Immuneering and 4 mentions for Ardelyx. Ardelyx's average media sentiment score of 1.02 beat Immuneering's score of 0.93 indicating that Ardelyx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immuneering	0 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

58.9% of Ardelyx shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 5.3% of Ardelyx shares are held by company insiders. Comparatively, 22.9% of Immuneering shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Ardelyx has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Immuneering has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market.

Immuneering has lower revenue, but higher earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$407.32M	3.12	-$61.60M	-$0.23	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A

Summary

Immuneering beats Ardelyx on 8 of the 15 factors compared between the two stocks.

How does Immuneering compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Immuneering's return on equity of -31.93% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Immuneering	N/A	-31.93%	-29.92%

Corvus Pharmaceuticals presently has a consensus price target of $33.33, indicating a potential upside of 126.60%. Immuneering has a consensus price target of $16.57, indicating a potential upside of 221.15%. Given Immuneering's stronger consensus rating and higher probable upside, analysts plainly believe Immuneering is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Immuneering had 5 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 6 mentions for Immuneering and 1 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.87 beat Immuneering's score of 0.93 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Corvus Pharmaceuticals	Very Positive
Immuneering	Positive

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 22.9% of Immuneering shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Corvus Pharmaceuticals has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market. Comparatively, Immuneering has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A

Summary

Immuneering beats Corvus Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Immuneering compare to Capricor Therapeutics?

Immuneering (NASDAQ:IMRX) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Immuneering has higher earnings, but lower revenue than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A
Capricor Therapeutics	$22.27M	53.59	-$105.04M	-$2.32	N/A

In the previous week, Immuneering had 4 more articles in the media than Capricor Therapeutics. MarketBeat recorded 6 mentions for Immuneering and 2 mentions for Capricor Therapeutics. Immuneering's average media sentiment score of 0.93 beat Capricor Therapeutics' score of 0.63 indicating that Immuneering is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Capricor Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.7% of Immuneering shares are owned by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are owned by institutional investors. 22.9% of Immuneering shares are owned by insiders. Comparatively, 9.2% of Capricor Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Immuneering has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

Immuneering currently has a consensus target price of $16.57, indicating a potential upside of 221.15%. Capricor Therapeutics has a consensus target price of $53.67, indicating a potential upside of 160.39%. Given Immuneering's higher possible upside, research analysts plainly believe Immuneering is more favorable than Capricor Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Immuneering's return on equity of -31.93% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-31.93%	-29.92%
Capricor Therapeutics	N/A	-59.27%	-48.65%

Summary

Immuneering beats Capricor Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Immuneering compare to Savara?

Savara (NASDAQ:SVRA) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

87.9% of Savara shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 5.3% of Savara shares are held by company insiders. Comparatively, 22.9% of Immuneering shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Savara currently has a consensus price target of $10.14, indicating a potential upside of 76.70%. Immuneering has a consensus price target of $16.57, indicating a potential upside of 221.15%. Given Immuneering's higher possible upside, analysts plainly believe Immuneering is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Immuneering's return on equity of -31.93% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-87.19%	-66.42%
Immuneering	N/A	-31.93%	-29.92%

Savara is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.56	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A

In the previous week, Immuneering had 5 more articles in the media than Savara. MarketBeat recorded 6 mentions for Immuneering and 1 mentions for Savara. Savara's average media sentiment score of 1.87 beat Immuneering's score of 0.93 indicating that Savara is being referred to more favorably in the media.

Company	Overall Sentiment
Savara	Very Positive
Immuneering	Positive

Savara has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Immuneering has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

Summary

Immuneering beats Savara on 8 of the 13 factors compared between the two stocks.

How does Immuneering compare to Avalyn Pharma?

Immuneering (NASDAQ:IMRX) and Avalyn Pharma (NASDAQ:AVLN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

67.7% of Immuneering shares are owned by institutional investors. 22.9% of Immuneering shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Avalyn Pharma's return on equity of 0.00% beat Immuneering's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-31.93%	-29.92%
Avalyn Pharma	N/A	N/A	N/A

Immuneering is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A

In the previous week, Immuneering had 3 more articles in the media than Avalyn Pharma. MarketBeat recorded 6 mentions for Immuneering and 3 mentions for Avalyn Pharma. Immuneering's average media sentiment score of 0.93 beat Avalyn Pharma's score of 0.62 indicating that Immuneering is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immuneering presently has a consensus price target of $16.57, indicating a potential upside of 221.15%. Avalyn Pharma has a consensus price target of $59.00, indicating a potential upside of 111.93%. Given Immuneering's higher probable upside, research analysts plainly believe Immuneering is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20

Summary

Immuneering beats Avalyn Pharma on 7 of the 12 factors compared between the two stocks.

Get Immuneering News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMRX vs. The Competition

Export

Metric	Immuneering	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$330.60M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-4.41	20.85	27.15	24.26
Price / Sales	N/A	314.01	587.92	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	1.53	8.49	10.75	6.29
Net Income	-$56.03M	$23.83M	$3.58B	$330.66M
7 Day Performance	1.18%	-3.56%	-2.07%	-1.32%
1 Month Performance	23.15%	6.31%	3.31%	-0.64%
1 Year Performance	23.74%	48.30%	26.35%	19.08%

Immuneering Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMRX Immuneering	3.1098 of 5 stars	$5.16 +1.0%	$16.57 +221.2%	+16.7%	$330.60M	N/A	N/A	60	News Coverage Analyst Upgrade
ARDX Ardelyx	3.3877 of 5 stars	$5.41 +1.2%	$15.73 +191.0%	+14.5%	$1.34B	$407.32M	N/A	90
CRVS Corvus Pharmaceuticals	2.8962 of 5 stars	$15.80 +4.1%	$33.33 +111.0%	+255.3%	$1.33B	N/A	N/A	30
CAPR Capricor Therapeutics	2.5473 of 5 stars	$22.09 -1.5%	$53.67 +142.9%	+169.8%	$1.29B	$22.27M	N/A	101
SVRA Savara	2.3784 of 5 stars	$6.26 +0.9%	$10.14 +62.2%	+140.2%	$1.28B	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMRX) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immuneering (IMRX) Competitors

IMRX vs. ARDX, CRVS, CAPR, SVRA, and AVLN

How does Immuneering compare to Ardelyx?

Summary

How does Immuneering compare to Corvus Pharmaceuticals?

Summary

How does Immuneering compare to Capricor Therapeutics?

Summary

How does Immuneering compare to Savara?

Summary

How does Immuneering compare to Avalyn Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRX vs. The Competition

Immuneering Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immuneering (IMRX) Competitors

IMRX vs. ARDX, CRVS, CAPR, SVRA, and AVLN

How does Immuneering compare to Ardelyx?

Is ARDX or IMRX more profitable?

Do analysts prefer ARDX or IMRX?

Does the media prefer ARDX or IMRX?

Do insiders & institutionals hold more shares of ARDX or IMRX?

Which has more volatility and risk, ARDX or IMRX?

Which has preferable valuation and earnings, ARDX or IMRX?

Summary

How does Immuneering compare to Corvus Pharmaceuticals?

Is CRVS or IMRX more profitable?

Do analysts rate CRVS or IMRX?

Does the media refer more to CRVS or IMRX?

Do institutionals and insiders believe in CRVS or IMRX?

Which has more risk and volatility, CRVS or IMRX?

Which has preferable valuation and earnings, CRVS or IMRX?

Summary

How does Immuneering compare to Capricor Therapeutics?

Which has preferable valuation and earnings, IMRX or CAPR?

Does the media prefer IMRX or CAPR?

Do insiders & institutionals hold more shares of IMRX or CAPR?

Which has more volatility and risk, IMRX or CAPR?

Do analysts prefer IMRX or CAPR?

Is IMRX or CAPR more profitable?

Summary

How does Immuneering compare to Savara?

Do insiders and institutionals hold more shares of SVRA or IMRX?

Do analysts recommend SVRA or IMRX?

Is SVRA or IMRX more profitable?

Which has preferable valuation & earnings, SVRA or IMRX?

Does the media prefer SVRA or IMRX?

Which has more risk and volatility, SVRA or IMRX?

Summary

How does Immuneering compare to Avalyn Pharma?

Do insiders & institutionals believe in IMRX or AVLN?

Is IMRX or AVLN more profitable?

Which has stronger earnings & valuation, IMRX or AVLN?

Does the media prefer IMRX or AVLN?

Do analysts rate IMRX or AVLN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRX vs. The Competition

Immuneering Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools